

ORION INFUSION LIMITED
CONDENSED INTERIM FINANCIAL STATEMENTS (UN-AUDITED)
AS AT AND FOR PERIOD ENDED DECEMBER 31, 2024
(HALF YEARLY)

ORION INFUSION LIMITED
CONDENSED STATEMENT OF FINANCIAL POSITION
AS AT DECEMBER 31, 2024

Particulars	Notes	Amount in Taka	
		31-Dec-24	30-Jun-24
ASSETS			
Non-Current Assets:		385,317,047	386,866,502
Property, Plant & Equipment	05.00	350,129,873	352,385,481
Right-of-use Assets	06.00	11,604,545	11,764,172
Investments	07.00	23,582,629	22,716,849
Current Assets:		458,799,010	437,876,717
Inventories	08.00	147,522,968	139,509,706
Trade and other Receivables	09.00	138,952,606	124,829,387
Advances, Deposits & Prepayments	10.00	159,474,497	151,196,022
Cash and Cash Equivalents	11.00	12,848,939	22,341,602
TOTAL ASSETS		844,116,057	824,743,219
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' Equity:		312,083,017	314,623,659
Share Capital	12.00	203,597,600	203,597,600
Retained Earnings		(26,731,261)	(24,044,910)
Reserves	13.00	135,216,678	135,070,969
Non-Current Liabilities:		26,636,934	26,609,667
Lease Obligation	14.00	6,882,776	7,023,900
Deferred Tax Liabilities	15.00	19,754,158	19,585,767
Current Liabilities:		505,396,107	483,509,893
Current Portion of Lease Obligation	14.01	6,075,022	6,160,348
Short Term Loans	16.00	308,994,635	305,152,114
Trade and Other Payables	17.00	45,324,315	53,204,533
Accrued Expenses	18.00	96,125,192	94,202,349
Unclaimed/Unpaid Dividend		48,876,943	24,790,549
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		844,116,057	824,743,219
Net Asset Value (NAV) Per Share of Tk. 10 Each		15.33	15.45
Number of Shares used to compute NAV		20,359,760	20,359,760

Sd/-
Sd/-
Sd/-
Sd/-
Sd/-
Chairman
Managing Director
Director
Chief Financial Officer
Company Secretary

ORION INFUSION LIMITED
CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED DECEMBER 31, 2024 (HALF YEARLY)

Particulars	Note	Amount in Taka			
		July to December 2024	July to December 2023	October to December 2024	October to December 2023
Revenue	19	393,689,779	438,586,393	195,047,429	202,732,395
Cost of Goods Sold		(232,566,541)	(265,205,480)	(115,704,917)	(121,594,620)
Gross Profit		161,123,238	173,380,913	79,342,512	81,137,775
Operating Expenses		(113,261,193)	(127,851,193)	(56,046,902)	(61,044,367)
Administrative Expenses		(17,156,407)	(19,746,407)	(8,310,193)	(9,987,743)
Selling & Distribution Expenses		(96,104,786)	(108,104,786)	(47,736,709)	(51,056,624)
Profit from Operation		47,862,045	45,529,720	23,295,610	20,093,408
Financial Expenses	20	(20,391,174)	(16,204,663)	(10,396,253)	(8,614,051)
Non Operating Income / (Loss)	21	474,431	565,783	377,955	186,468
Net Profit from Operation		27,945,303	29,890,840	13,277,312	11,665,825
Workers' Profit Participation Fund		(1,330,729)	(1,423,373)	(632,253)	(555,515)
Net Profit Before Tax		26,614,574	28,467,467	12,645,059	11,110,310
Income Tax expense	22	(5,646,829)	(6,769,089)	(2,702,282)	(2,803,795)
Current Tax	22.01	(5,322,915)	(6,400,637)	(2,529,012)	(2,497,777)
Deferred Tax Income/(Expenses)		(323,914)	(368,452)	(173,271)	(306,018)
Net Profit After Tax		20,967,745	21,698,378	9,942,777	8,306,515
Add: Other Comprehensive Income		777,915	2,109,431	978,944	2,920,579
Fair Value Adjustment of Marketable Securities		622,392	(468,978)	901,182	(271,737)
Deferred Tax Income/(Expense) on Revaluation Surplus on PPE		155,523	2,578,409	77,762	3,192,316
Total Comprehensive Income		21,745,660	23,807,809	10,921,720	11,227,094
Earning Per Share	23	1.03	1.07	0.49	0.41

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION INFUSION LIMITED
CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED DECEMBER 31, 2024 (HALF YEARLY)

Particulars	<u>Amount in Taka</u>			
	Ordinary Share Capital	Retained Earnings	Reserves	Total
Balance at July 01, 2024	203,597,600	(24,044,910)	135,070,969	314,623,660
Net Profit during the Period	-	20,967,745	-	20,967,745
Cash Dividend for the year 2023-2024	-	(24,431,712)	-	(24,431,712)
Fair value adjustment for sell of marketable securities	-	-	145,409	145,409
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	777,615	(777,615)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	622,392	622,392
Adjustment for deferred tax on Revaluation Surplus	-	-	155,523	155,523
Balance at December 31, 2024	203,597,600	(26,731,261)	135,216,678	312,083,017

FOR THE PERIOD ENDED DECEMBER 31, 2023 (HALF YEARLY)

Particulars	<u>Amount in Taka</u>			
	Ordinary Share Capital	Retained Earnings	Reserves	Total
Balance at July 01, 2023	203,597,600	(48,438,652)	136,493,515	291,652,463
Net Profit during the Period	-	21,698,378	-	21,698,378
Cash Dividend for the year (2022-2023)	-	(20,359,760)	-	(20,359,760)
Fair value adjustment for sell of marketable securities	-	-	22,978	22,978
Transfer between Reserve & Retained earnings for depreciation on Revaluation surplus.	-	818,542	(818,542)	-
Fair Value Gain/(Loss) on Marketable Securities	-	-	(468,978)	(468,978)
Adjustment for Right-of-use Assets	-	690,826	-	690,826
Adjustment for deferred tax on Revaluation Surplus	-	-	2,578,409	2,578,409
Balance at December 31, 2023	203,597,600	(45,590,666)	137,807,380	295,814,314

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director
3

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION INFUSION LIMITED
CONDENSED STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED DECEMBER 31, 2024 (HALF YEARLY)

Particulars	Note	Amount in Taka	
		July to December 2024	July to December 2023
Cash Flows from Operating Activities :			
Receipts :			
Cash received from Customers		379,566,560	435,273,103
Other Income / (Loss)		474,431	565,783
		380,040,991	435,838,885
Payments :			
Cash paid to Suppliers		(241,782,328)	(251,730,012)
Cash paid for operating Expenses		(110,219,413)	(146,308,523)
Cash paid for Financial Expenses		(20,391,174)	(16,204,663)
Income Tax paid and Deducted at Source		(12,004,887)	(13,805,078)
		(384,397,803)	(428,048,276)
Net Cash Received / (Used) from Operating Activities		(4,356,811)	7,790,609
Cash Flows from Investing Activities :			
Acquisition of Property, Plant & Equipments		(5,058,957)	(9,274,002)
Received from / (Payment to) Securities & Others		(97,980)	(6,600)
Net Cash Received / (Used) from Investing Activities		(5,156,937)	(9,280,602)
Cash Flows from Financing Activities :			
Increase/ (Decrease) in Liabilities for Other Finance		(3,476,118)	(5,447,643)
Dividend Paid		(345,318)	(21,170)
Bank Loans Received / (Repaid)		3,842,521	(21,782,210)
Net Cash Received / (Used) from Financing Activities		21,084	(27,251,023)
Net Increase / (Decrease) in Cash & Cash Equivalents		(9,492,664)	(28,741,017)
Cash & Cash Equivalents at the beginning of the period		22,341,602	44,991,235
Cash & Cash Equivalents at the End of the Period		12,848,939	16,250,219
Net Operating Cash Flow Per Share	26	(0.21)	0.38
Number of Shares used to compute NOCFPS		20,359,760	20,359,760

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION INFUSION LIMITED
Notes, comprising a summary of significant accounting policies
and other explanatory information
As at and for the period ended December 31, 2024

01.00 Reporting Entity

01.01 Background of the Entity

Orion Infusion Limited is a public limited company incorporated in Bangladesh on 05 May 1983 and is now operating under the banner of Orion Group. The Company was converted into a public limited company on 05 October 1994. The registered office of the company "Orion House" is situated at 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh. Production plant of the company is situated at Maikuli, P.S.-Rupganj, and District- Naraynganj, Bangladesh.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996.

01.02 Nature of Business

Orion Infusion Limited is devoted in producing Large Volume Parenteral (LVP) & other lifesaving injectable products. The company has the manufacturing facilities for the production of I.V. Rehydration Solutions, Electrolyte Solutions, and Solution for Acidosis, Ranitidine I.V. infusion, Anti-Microbial products viz. Ciprofloxacin I.V., Metronidazole I.V. etc. To meet the tremendous increment of the demand of its products, Orion Infusion Ltd. is now set to expand its production capacity further by installing modern and sophisticated technologies which will certainly rich its core competence. The company is now producing pure steam generated fluids, required by GMP instead of Black steam generated fluids. Innovative product like Amino acids solution was introduced by Orion Infusion Ltd., which was the first ever manufactured in Bangladesh and this has given Orion Infusion Ltd. a competitive advantage over others. Orion Infusion Ltd. Quality Manual describes the quality policies & company wide control structure of the quality management system (QMS), which is leading towards achieving its corporate vision and mission.

02.00 Basis of Preparation and Presentation of Financial Statements

02.01 Statement of Compliance

The financial statements have been prepared in accordance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, Securities and Exchange Rules 1987 and other relevant local laws as applicable.

02.02 Components of the Condensed Financial Statements

According to IAS-34 " Interim Financial Reporting," these interim financial statements include the following components-

- i. Condensed Statement of Financial Position
- ii. Condensed Statement of Profit or Loss and other Comprehensive Income
- iii. Condensed Statement of Changes in Equity
- iv. Condensed Statement of Cash Flows
- v. Selected Explanatory Notes to the Condensed Financial Statements

02.03 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

02.04 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka/Tk./BDT, which is the company's functional currency. The Company earns its major revenues in BDT and all other incomes/expenses and transactions are in BDT.

02.05 Comparative Information

Comparative information has been disclosed in respect of the year or period for all numerical information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

Comparative figures have been re-arranged where considered necessary to ensure better comparability with the current period without causing any impact on the profit and value of assets and liabilities as reported in the financial statements.

02.06 Reporting Period

The Financial period of the company covers from July 01, 2024 to December 31, 2024.

02.07 Use of Estimates and Judgments

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

02.08 Materiality, Aggregation and Off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the company has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of any asset or liability as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore. No such incident existed during the year.

02.09 Going Concern Review

As per IAS-1, a company is required to make assessment at the end of each year to make assessment of its capability to continue as going concern. Management of the company makes such assessment each year. The company has adequate resources to continue its operation for the foreseeable future and has wide coverage of its liabilities. For this reason, the directors continue to adopt going concern assumption while preparing the financial statements.

02.10 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on **January 29, 2025** for publication.

03.00 Accounting Policies and Methods of Computations

IFRS-16: Leases

In January 2016, the International Accounting Standards Board (IASB) issued IFRS-16 which is effective from annual reporting period beginning on or after 1 January 2019. The company has applied IFRS-16 Leases for the first time with the date of initial application of 01 July 2019.

IFRS 16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and requiring the recognition of a right-of-use asset and a lease liability at commencement for all leases.

The Company has applied IFRS 16 using the modified retrospective approach and therefore the comparative information has not been restated.

04.00 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

Note	Particulars	Amount in Taka	
		31.12.2024	30.06.2024
05.00	Property, Plant and Equipment		
	A) At Historical Cost		
	Opening Balance (At Cost)	659,561,953	648,147,365
	Add: Addition during the Period	5,058,957	11,414,588
	Less : Disposal during the Period	-	-
		664,620,910	659,561,953
	Opening Balance of Depreciation	456,303,041	442,574,946
	Charged during the Period	6,536,950	13,728,095
	Less : Disposal during the Period	-	-
	Accumulated depreciation	462,839,991	456,303,041
	Written down value	201,780,920	203,258,913
	B) At Revaluation		
	Opening Balance	166,981,322	166,981,322
	Add: Addition during the Period	-	-
		166,981,322	166,981,322
	Less: Depreciation		
	Opening Balance of Depreciation	17,854,753	16,217,668
	Charged during the Period	777,615	1,637,085
	Accumulated depreciation	18,632,369	17,854,753
	Written down value	148,348,953	149,126,569
	Total Carrying Value (A+B)	350,129,873	352,385,481
06.00	Right-of-use Assets		
	A) At Historical Cost		
	Opening Balance (At Cost)	57,195,190	58,744,047
	Add: Addition during the Period	3,249,668	2,032,485
		60,444,858	60,776,532
	Less: Disposal/ Adjustment	-	(3,581,342)
		60,444,858	57,195,190
	Opening Balance of Depreciation	45,431,018	37,518,846
	Charged during the Period	3,409,295	7,912,172
	Accumulated depreciation	48,840,313	45,431,018
	Written down value	11,604,545	11,764,172
07.00	Investments		
	Investment in Non-quoted Shares	16,825,396	16,825,396
	Investment in Marketable Securities	6,377,100	5,519,170
	Fixed Deposit (FDR), Agrani Bank, WASA Branch	380,133	372,283
		23,582,629	22,716,849

07.01 Investment in Non-quoted Shares

ICB Islamic Bank Ltd.

16,825,396	16,825,396
16,825,396	16,825,396

07.02 Investment in Marketable Securities**A. Southeast Bank Capital Services Ltd.**

Islami Bank Bangladesh Ltd.

Aftab Automobiles Ltd.

Sandhani Life Insurance Co. Ltd.

Associated Oxygen Limited

31.12.2024		30.06.2024	
Market Price	Cost Price	Market Price	Cost Price
-	-	3,260,000	4,528,494
4,410,450	4,618,624	-	-
603,900	1,297,726	744,200	1,297,726
101,400	234,217	106,200	234,217
5,115,750	6,150,567	4,110,400	6,060,437

B. Bank Asia Securities Ltd.

Premier Leasing & Finance

Eastern Housing Limited

66,150	387,418	74,970	387,419
1,195,200	2,263,745	1,333,800	2,263,745
1,261,350	2,651,163	1,408,770	2,651,163
6,377,100	8,801,730	5,519,170	8,711,601

08.00 Inventories

Raw Materials

Packing Materials

Work - in - process

Finished Goods

Promotional Materials

Printing & Stationeries

Goods in Transit

45,580,631	46,249,534
48,501,497	45,915,293
4,438,781	7,558,052
16,546,595	16,246,470
7,081,984	4,662,607
4,536,580	4,692,280
20,836,899	14,185,470
147,522,968	139,509,706

09.00 Trade and other receivables

Accounts Receivables

138,952,606	124,829,387
138,952,606	124,829,387

This is unsecured, considered good and is falling due within one year. Classification schedule as required by schedule XI of Companies Act 1994 are as follows:

Aging of the above balance is as follows:

Below 180 days

Above 180 days

138,952,606	124,829,387
-	-
138,952,606	124,829,387

Particulars	Amount in Taka	
	31.12.2024	30.06.2024
I. Accounts Receivable considered good in respect of which the company is fully secured	138,952,606	124,829,387
II. Accounts Receivable considered good in respect of which the company holds no security other than the debtor personal security	-	-
III. Accounts Receivable considered doubtful or bad	-	-
IV. Accounts Receivable due by any director or other officer of the company	-	-
V. Accounts Receivable due by Common Management	-	-
VI. The maximum amount of receivable due by any director or other officer of the company	-	-
Total	138,952,606	124,829,387

As at December 31, 2024 the company did not make any provision against trade receivables as there as no indication of impairment.

10.00 Advances, Deposits & Prepayments

Advances

Advance Income Tax	Note - 10.01	131,896,557	119,891,670
Travel and Other Advances		526,619	576,048
Advance paid to Suppliers		465,021	224,228
Advance for Office Rent		803,529	873,599
Motor Cycle & Car Advance		157,406	242,458
Advance against C&F		13,216,056	13,477,816
Advance Against Cash Purchase		40,360	303,027
		147,105,549	135,588,846

Deposits

Security Deposit	6,593,328	6,416,651
Bank Guarantee	3,376,793	3,376,793
Earnest Money	754,840	654,840
Collection & Other Advance	1,206,529	1,523,058
L/C Margin & Balance	437,458	3,635,834
	12,368,948	15,607,176
	159,474,497	151,196,022

10.01 Advance Income Tax

Opening Balance	119,891,670	96,833,116
Income tax paid and TDS during the period	12,004,887	23,058,554
	131,896,557	119,891,670

11.00 Cash and Cash Equivalents

Cash in Hand	985,921	1,316,734
(a) Cash in Hand/Imprest Cash	824,757	1,046,512
(b) Balance at Brokerage House	161,164	270,222
(c) Cash at Bank	11,863,018	21,024,868
Current Account (Main)	6,714,719	13,762,181
Current Account (Collection)	613,698	2,605,414
Short Term Deposit Account	4,534,601	4,657,273
Total	12,848,939	22,341,602

Note	Particulars	Amount in Taka	
		31.12.2024	30.06.2024

12.00 Share Capital

a) Authorized Capital

100,000,000 Ordinary Shares of Taka 10/- each

1,000,000,000 1,000,000,000

b) Issued, Subscribed and Paid-up Capital

20,359,760 Ordinary Shares of Taka 10/- each

203,597,600 203,597,600

c) Distribution Schedule

The detailed schedule showing the number of shareholders and their shareholding in percentage has been disclosed below as a requirement of the Regulation 37(3) of Dhaka Stock Exchange and Chittagong Stock Exchange.

Range of holding in number of shares	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31.12.2024	Percentage of Shareholding 30.06.2024
Up to 500 shares	5,209	1,263,846	6.21%	4.39%
501 to 5,000 shares	1,102	1,874,541	9.21%	13.19%
5,001 to 10,000 shares	112	905,004	4.45%	4.38%
10,001 to 20,000 shares	72	1,037,834	5.10%	3.44%
20,001 to above	90	15,278,535	75.04%	74.59%
Total	6,585	20,359,760	100%	100%

d) Shareholding Position as on December 31, 2024 is as follows:

Composition of Shareholding	No. of Shareholders	Number of Shares held	Percentage of Shareholding 31.12.2024	Percentage of Shareholding 30.06.2024
Sponsors	4	8,268,400	40.61%	40.61%
Foreign Investors	29	9,286	0.05%	0.05%
Institutional	267	3,363,111	16.52%	5.17%
General Public	6,285	8,718,963	42.82%	54.16%
Total	6,585	20,359,760	100%	100%

13.00 Reserves

Revaluation surplus on PPE

Note: 13.01

137,641,308

138,263,400

Fair value changes in investment

Note: 13.02

(2,424,630)

(3,192,431)

135,216,678

135,070,969

13.01 Revaluation surplus on Property, plant and equipment

Opening Balance

138,263,400

138,754,526

Depreciation on revalued asset

(777,615)

(1,637,085)

Adjustment for deferred tax on Revaluation Surplus

155,523

1,145,959

137,641,308

138,263,400

Note	Particulars	Amount in Taka	
		31.12.2024	30.06.2024
16.00	Short Term Loans		
	Agrani Bank C.C. (Hypothecation) - 54566, WASA Branch	206,265,515	206,382,450
	Agrani Bank (LTR), WASA Branch- 4786	102,729,120	98,769,664
		308,994,635	305,152,114
17.00	Trade and other payables		
	Trade Payables	45,324,315	53,204,533
		45,324,315	53,204,533
18.00	Accrued Expenses		
	Utilities	2,358,238	2,331,517
	Salary and Wages	13,357,904	16,185,342
	Employee Benefit Payable	8,877,588	7,546,859
	Audit Fee	-	287,500
	Corporate Governance Audit Fee	69,000	69,000
	Provision for Income Tax	69,808,175	64,485,260
	Others payable	1,654,288	3,296,871
		96,125,192	94,202,349
18.01	Provision for current tax		
	Opening Balance	64,485,260	54,886,848
	Add: Provision made during the period	5,322,915	9,769,704
	Less: Paid during the period	-	(171,292)
		69,808,175	64,485,260
19.00	Revenue		
	Local Sales	393,689,779	438,586,393
		393,689,779	438,586,393
20.00	Financial Expenses		
	Interest on C.C. (Hypo), Agrani Bank Ltd.	13,268,401	10,357,845
	Interest on LTR Loan Agrani Bank Ltd.	6,533,548	4,887,188
	Interest on Phoenix Finance & Investment Limited	-	169,819
	Finance Cost (Lease Obligation-Office Rent)	589,225	789,812
		20,391,174	16,204,663
21.00	Non Operating Income		
	Other Income	416,604	382,406
	Bank Interest	22,976	16,694
	Interest on FDR	9,412	7,941
	Capital Gain/(Loss) on Marketable Securities	(145,409)	(22,978)
	Dividend Income	170,848	181,720
		474,431	565,783

Particulars	Taxable Income	Taxable Amount	
		31.12.2024	31.12.2023
22.00 Income Tax Expense			
Current Tax on profit for the Period	Note - 25.01	5,322,915	6,400,637
Deferred tax expense/(income)		323,914	368,452
		5,646,829	6,769,089
Taxable profit	26,443,726	5,288,745	6,364,293
Dividend income	170,848	34,170	36,344
Total	26,614,574	5,322,915	6,400,637

Minimum Tax

Calculation of gross receipt

Revenue:

Sales		393,689,779	438,586,393
Other Income		416,604	382,406
Interest on FDR		9,412	7,941
Capital Gain/(Loss) on Marketable Securities		-	(22,978)
Total Gross Receipts		394,115,795	438,953,763
Minimum Tax (0.60% On Total Gross Receipts)		2,364,695	2,633,723

Disclosures as per BSEC NOTIFICATION No. BSEC/CMRRCD/2006-158/208/ADMIN/81 Dated 20 June, 2018

23.00 Earning Per Share (EPS)

The computation is given below

Net Profit After Tax	20,967,745	21,698,378
Ordinary shares outstanding during the Period	20,359,760	20,359,760
	1.03	1.07

24.00 Acquisition of Property Plant & Equipments during the period

SL. NO.	Particulars	Amount in Taka	
		31.12.2024	31.12.2023
1	Building	-	1,166,918
2	Plant & Machinery	2,568,426	4,922,084
3	Office Equipment	2,490,531	3,185,000
Total		5,058,957	9,274,002

Note	Particulars	Amount in Taka	
		01.07.2024 to 31.12.2024	01.07.2023 to 31.12.2023

25.00 Reconciliation of net profit with cash flows from operating activities

Net Profit before tax	26,614,574	28,467,467
Interest & other income	(474,431)	(565,783)
Financial Expenses	20,391,174	16,204,663
(Increase) / Decrease in accounts receivables	(14,123,219)	(3,313,291)
Increase in Inventory	(8,013,262)	11,570,685
Increase / (Decrease) in trade payable	(7,880,218)	(5,121,433)
Increase / (Decrease) in accrued expenses	(3,400,072)	(935,542)
Depreciation	10,723,861	12,138,114
Increase in Advance, Deposit & Prepayments	3,726,412	(21,210,313)
Cash generated from operating activities	27,564,819	37,234,567
Investment Income	474,431	565,783
Finance Cost paid	(20,391,174)	(16,204,663)
Income taxes paid	(12,004,887)	(13,805,078)
Net cash flows from operating activities	(4,356,811)	7,790,609

26.00 Calculation of Net operating cash flow per share (NOCFPS)

Net Cash flow from operating activities	(4,356,811)	7,790,609
No. of Shares	20,359,760	20,359,760
Net operating cash flow per share (NOCFPS)	(0.21)	0.38

NOCFPS decreased to (0.21) than 0.38 of the previous corresponding period. During the period cash received from customer is decreased than the previous corresponding period.

2700 Calculation of Net Asset Value Per Share

Total Assets	844,116,057	824,743,219
Total Liabilities	532,033,040	510,119,559
Net Assets	312,083,017	314,623,660
No. of Share	20,359,760	20,359,760
Net Asset Value (NAV) Per Share	15.33	15.45

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary